From the Departments of Cardiothoracic Anesthesia (A.E.D.) Outcomes Research (A.E.D., D.I.S., A.A.-E., S.B., T. Said, M.M.-C., H.C., E.J.M., D.Y.) Quantitative Health Sciences (E.J.M., D.Y.) Thoracic and Cardiovascular Surgery (A.M.G.), Cleveland Clinic, Cleveland, Ohio the Department of Anesthesia, Royal Victoria Hospital, McGill University, Montreal, Canada (H.S., T. Sato, K.N., G.C., R.H., T.C.-M., T. Schricker) Current positions: Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin (A.A.-E.) Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Boston, Massachusetts (S.B.) Departments of Family Medicine and Geriatric Medicine, Metro Health Medical Center, Cleveland, Ohio (T. Said) Southern Arizona Anesthesia, Tucson, Arizona (M.M.-C.) the Department of Anesthesiology, University of Cincinnati, Cincinnati, Ohio (H.C.).
Anesthesiology. 2018 Jun;128(6):1125-1139. doi: 10.1097/ALN.0000000000002156.
Hyperinsulinemic normoglycemia augments myocardial glucose uptake and utilization. We tested the hypothesis that hyperinsulinemic normoglycemia reduces 30-day mortality and morbidity after cardiac surgery.
This dual-center, parallel-group, superiority trial randomized cardiac surgical patients between August 2007 and March 2015 at the Cleveland Clinic, Cleveland, Ohio, and Royal Victoria Hospital, Montreal, Canada, to intraoperative glycemic management with (1) hyperinsulinemic normoglycemia, a fixed high-dose insulin and concomitant variable glucose infusion titrated to glucose concentrations of 80 to 110 mg · dl; or (2) standard glycemic management, low-dose insulin infusion targeting glucose greater than 150 mg · dl. The primary outcome was a composite of 30-day mortality, mechanical circulatory support, infection, renal or neurologic morbidity. Interim analyses were planned at each 12.5% enrollment of a maximum 2,790 patients.
At the third interim analysis (n = 1,439; hyperinsulinemic normoglycemia, 709, standard glycemic management, 730; 52% of planned maximum), the efficacy boundary was crossed and study stopped per protocol. Time-weighted average glucose concentration (means ± SDs) with hyperinsulinemic normoglycemia was 108 ± 20 versus 150 ± 33 mg · dl with standard glycemic management, P < 0.001. At least one component of the composite outcome occurred in 49 (6.9%) patients receiving hyperinsulinemic normoglycemia versus 82 (11.2%) receiving standard glucose management (P < efficacy boundary 0.0085); estimated relative risk (95% interim-adjusted CI) 0.62 (0.39 to 0.97), P = 0.0043. There was a treatment-by-site interaction (P = 0.063); relative risk for the composite outcome was 0.49 (0.26 to 0.91, P = 0.0007, n = 921) at Royal Victoria Hospital, but 0.96 (0.41 to 2.24, P = 0.89, n = 518) at the Cleveland Clinic. Severe hypoglycemia (less than 40 mg · dl) occurred in 6 (0.9%) patients.
Intraoperative hyperinsulinemic normoglycemia reduced mortality and morbidity after cardiac surgery. Providing exogenous glucose while targeting normoglycemia may be preferable to simply normalizing glucose concentrations.
高胰岛素正常血糖可增加心肌葡萄糖摄取和利用。我们检验了这样一个假设,即在心脏手术后,高胰岛素正常血糖可降低 30 天死亡率和发病率。
这是一项双中心、平行组、优效性试验,于 2007 年 8 月至 2015 年 3 月在克利夫兰诊所(克利夫兰,俄亥俄州)和加拿大蒙特利尔皇家维多利亚医院之间进行,将接受心脏手术的患者随机分配至术中血糖管理,其中包括(1)高胰岛素正常血糖,使用固定的高剂量胰岛素和同时输注可变葡萄糖,使血糖浓度维持在 80 至 110mg·dl;或(2)标准血糖管理,使用低剂量胰岛素输注使血糖大于 150mg·dl。主要结局是 30 天死亡率、机械循环支持、感染、肾脏或神经功能障碍的复合结局。计划在最大 2790 例患者的每 12.5%入组时进行中间分析。
在第三次中间分析(n=1439;高胰岛素正常血糖组 709 例,标准血糖管理组 730 例;占计划最大人数的 52%)时,根据方案,疗效边界已越过,试验停止。高胰岛素正常血糖组的时间加权平均血糖浓度(均数±标准差)为 108±20mg·dl,而标准血糖管理组为 150±33mg·dl,P<0.001。高胰岛素正常血糖组有至少一个复合结局组成部分的患者为 49(6.9%)例,而标准血糖管理组为 82(11.2%)例(P<疗效边界 0.0085);估计的相对风险(95%中间调整 CI)为 0.62(0.39 至 0.97),P=0.0043。存在治疗与地点的交互作用(P=0.063);复合结局的相对风险在皇家维多利亚医院为 0.49(0.26 至 0.91,P=0.0007,n=921),但在克利夫兰诊所为 0.96(0.41 至 2.24,P=0.89,n=518)。严重低血糖(<40mg·dl)发生在 6(0.9%)例患者中。
术中高胰岛素正常血糖可降低心脏手术后的死亡率和发病率。在目标正常血糖的同时提供外源性葡萄糖可能优于简单地使葡萄糖浓度正常化。